Skip to main content

Table 1 Patient characteristics

From: A randomized controlled pilot study to evaluate the effect of an enteral formulation designed to improve gastrointestinal tolerance in the critically ill patient—the SPIRIT trial

  Peptamen® AF (n = 46) Isosource® Energy (n = 44)
Age, years n = 46 65.3 (52.6–75.3) n = 44 61.6 (48.6–71.3)
Sex, male n = 46 33 (72%) n = 44 28 (64%)
Body mass index, kg/m2 n = 41 28.8 (25.1–34.2) n = 41 27.8 (23.5–31.5)
APACHE II admission diagnosis n = 44 28.5 (22.3–32.8) n = 42 27.5 (22.0–33.3)
SAPS II admission diagnosis n = 46 60.5 (46.5–74.0) n = 44 61.5 (48.5–75.5)
SOFA n = 45 8.0 (6.0–11.0) n = 44 7.0 (5.0–10.0)
Mechanical ventilation n = 46 43 (94%) n = 44 43 (98%)
Treated with vasoactive drugs n = 46 31 (67%) n = 44 29 (66%)
Diabetes n = 46 13 (28%) n = 44 8 (18%)
Residual gastric volume at study inclusion, ml n = 42 35.0 (10.0–112.5) n = 43 50.0 (20.0–100.0)
Presence of diarrhea at study inclusion n = 46 5 (11%) n = 44 4 (9%)
Blood glucose at study inclusion, mmol/l n = 46 7.8 (6.8–8.9) n = 44 8.3 (6.9–9.4)
  1. Continuous variables are presented as median (interquartile range) and categorical variables as number of patients (%)
  2. APACHE Acute Physiology and Chronic Health Evaluation, SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment